FBRX Forte Biosciences, Inc.
USHealthcareAs of 2026-07-10 16:00
Why FBRX matters now
Forte Biosciences, Inc. (FBRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $43.92 with +19.67% on the session and $609.9M in market capitalization; recent performance reads 1-month -11.06% and YTD -34.54%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-22.1M, and EPS of $-1.24. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -24.0%.
The latest indexable market news headline is "FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $65.00; recent insider activity includes Wagner Paul A. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
75.63
P/S
0.00
EV/EBITDA
-2.55
DCF Value
$0.47
FCF Yield
-24.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-106.2%
ROA
-112.8%
ROIC
-176.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-22.1M | $-1.24 |
| Q4 2025 | $0.00 | $-24.8M | $-1.39 |
| FY 2025 | $0.00 | $-69.4M | $-4.71 |
| Q3 2025 | $0.00 | $-17.7M | $-0.99 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$65.00
Target (Median)
$65.00
Target Range
$65.00 - $65.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.87
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.